Loading...
We have set up our new Discord server! Share your feedback and find like-minded people! Join our Discord
- Ticker
- MEDCL.PA
- Price
- 16.92
- Stock movement up
- +0.35 (2.11%)
- Company name
- Medincell SA
- Exchange
- (PA ,
- Currency
- EUR )
- Sector
- Healthcare >Biotechnology
- Markedsværdi
- 492.22M
- Ent værdi
- 550.53M
- Pris/omsætning
- 38.17
- Pris/bog
- -
- Udbytte afkast
- -
- Udbyttevækst
- -
- Vekst år
- -
- FCF-udbetaling
- -107.13%
- Efterfølgende P/E
- -
- Fremtidig P/E
- 423.00
- PEG
- -
- EPS-vekst
- -4.66%
- 1 års afkast
- 25.15%
- 3 års afkast
- 50.13%
- 5 års afkast
- 16.63%
- 10 års afkast
- -
Senest opdateret: 2025-06-22
UDBYTTE
MEDCL.PA betaler ikke udbytte
VÆRDIANSÆTTELSE
Værdiansættelsesforhold
Loading...
Værdiansættelsesforhold-data
| Efterfølgende P/E | - |
| Pris til OCF | - |
| Pris til FCF | - |
| Pris til EBITDA | - |
| EV i forhold til EBITDA | - |
Værdiansættelse (salg/bogført værdi)
Loading...
Værdiansættelse (salg/bogført værdi)-data
| Pris til omsætning | 38.17 |
| Pris til egenkapital | - |
| EV i forhold til salg | 42.70 |
ØKONOMI
Pr. aktie
Loading...
Data pr. aktie
| Aktuelt antal aktier | 29.09M |
| EPS (TTM) | -1.55 |
| FCF pr. aktie (TTM) | -1.24 |
Resultatopgørelse
Loading...
Resultatopgørelse-data
| Omsætning (TTM) | 12.89M |
| Bruttofortjeneste (TTM) | 16.17M |
| Driftsindkomst (TTM) | -38.34M |
| Nettoindkomst (TTM) | -43.30M |
| EPS (TTM) | -1.55 |
| EPS (1 år frem) | 0.04 |
Marginer
Loading...
Marginer-data
| Bruttomargin (TTM) | 125.43% |
| Driftsmargin (TTM) | -297.37% |
| Fortjenstmargin (TTM) | -335.82% |
Balance
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Balancedata
| Kontanter | 19.46M |
| Nettotilgodehavender | 2.25M |
| Omsætningsaktiver i alt | 27.26M |
| Goodwill | -1.00K |
| Immaterielle aktiver | 2.45M |
| Ejendomme, anlæg og udstyr | 10.83M |
| Sum aktiver | 36.95M |
| Kreditor | 1.85M |
| Kortfristet/nuværende langsigtet gæld | 58.96M |
| Summen af kortfristede forpligtelser | 16.47M |
| Sum gæld | 77.77M |
| Aktionærernes egenkapital | -40.82M |
| Materielle nettoaktiver | 0.00 |
Likviditet
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Kontantstrøm-data
| Likviditet fra driften (TTM) | -33.60M |
| Investeringsudgifter (TTM) | 1.08M |
| Fri pengestrøm (TTM) | -34.69M |
| Udbetalt udbytte (TTM) | 37.16M |
Finansiel indkomst
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Data om finansiel indkomst
| Egenkapitalafkast | - |
| Afkast af aktiver | -117.19% |
| Afkast af investeret kapital | 106.07% |
| Kontant afkast af investeret kapital | 84.97% |
INFORMATION OM AKTIER
Aktiediagram
Loading...
Aktiekurs-data
| Åbning | 16.78 |
| Daglig høj | 17.50 |
| Daglig lav | 16.53 |
| Daglig volumen | 186K |
| Højeste gennem alle tider | 18.64 |
| 1 års analytiker estimat | 22.37 |
| Beta | 1.20 |
| EPS (TTM) | -1.55 |
| Udbytte pr. aktie | - |
| Ex-div dato | - |
| Næste dato for resultatpræsentation | 12 Sep 2025 |
Nedsidepotensial
Loading...
Nedsidepotensial-data
| MEDCL.PA | S&P500 | |
| Nuværende prisfald fra top notering | -9.23% | -3.04% |
| Højeste prisfald | -70.46% | -56.47% |
| Højeste efterår dato | 25 Aug 2022 | 9 Mar 2009 |
| Gennemsnitlig fald fra toppen | -33.99% | -11.04% |
| Gennemsnitlig tid til nyt højdepunkt | 82 days | 12 days |
| Maks. tid til nyt højdepunkt | 862 days | 1805 days |
OPLYSNINGER OM VIRKSOMHEDEN
Markedsværdi
492.22M
Markedsværdi kategori
Small-cap
Beskrivelse
MedinCell S.A., a pharmaceutical company, develops long acting injectables in various therapeutic areas in France. It develops solutions based on BEPO, a long-acting injectable technology; and offers UZEDY (mdc-IRM) for the treatment of schizophrenia in adults. The company's products in development include mdc-CWM, a sustained-release formulation of celecoxib in Phase III trials for use in the treatment of reduction of postoperative pain and inflammation; and mdc-TJK, a subcutaneous injection that is in Phase III clinical trials for use in the treatment of schizophrenia. Its product candidates in preclinical trials include mdc-WWM for contraception; and mdc-STM for malaria. MedinCell S.A. was incorporated in 2003 and is headquartered in Jacou, France.
Personale
134
Hjemmeside
Investor relationer
-
SEC-indsendelser
Adm. direktør
Land
France
By
Aktietype
-
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRÆSENTATIONER
ArrangementerPræsentationer
Loading...
FORSTÅ FORRETNINGEN
Loading...
NYHEDER OM VIRKSOMHEDEN
Alle nyhederPressemeddelelser
As the European markets navigate a landscape marked by geopolitical tensions and economic adjustments, indices like the STOXX Europe 600 have experienced declines amid concerns over Middle East unrest...
26. juni 2025
MONTPELLIER, France, June 17, 2025--Regulatory News: Medincell (Paris:MEDCL):
17. juni 2025
MONTPELLIER, France, June 10, 2025--Regulatory News: Medincell (Paris:MEDCL) will host two live videoconferences on Tuesday, June 17, 2025, to present its financial results for the fiscal year ending ...
10. juni 2025
MONTPELLIER, France, May 28, 2025--Regulatory News: Christophe Douat, Chief Executive Officer, and Dr. Richard Malamut, Chief Medical Officer, will present Medincell’s (Paris:MEDCL) corporate overview...
28. maj 2025
MONTPELLIER, France, May 28, 2025--Regulatory News: Medincell (Paris:MEDCL):
28. maj 2025
The European stock market recently experienced a downturn, with the pan-European STOXX Europe 600 Index ending lower amid trade tensions and economic uncertainty. In this environment, growth companies...
27. maj 2025
As European markets experience a boost in sentiment following the de-escalation of U.S.-China trade tensions, major indices such as the STOXX Europe 600 have shown positive performance. In this contex...
23. maj 2025
MONTPELLIER, France, May 07, 2025--Regulatory News: Medincell’s partner Teva Pharmaceuticals shared today the following information:
7. maj 2025
As trade tensions between the U.S. and China show signs of easing, European markets have responded positively, with major indices like Germany's DAX and France's CAC 40 seeing notable gains. Against t...
28. april 2025
As European markets show signs of recovery, with the pan-European STOXX Europe 600 Index climbing 3.93% amid positive sentiment from delayed tariffs and potential ECB rate cuts, investors are increasi...
23. april 2025
Næste side